- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05529940
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
Efficacy of Perioperative Versus Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: an International Multicenter Randomized Controlled Trial (NeoFOL-R Trial)
Rationale: Adjuvant chemotherapy after surgery significantly improved the survival of PC patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesion which are not being detected in early diseases status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting. Asians differ from Westerners not only in racial differences, but also in average size and body surface area. Accordingly, there is an urgent need for clinical studies on the dose, toxicity, dosing cycle, and efficacy of anticancer drugs that reflect actual clinical trials in Asian countries for Asians. There are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC.
Obective: To investigate whether 6 cycles of preoperative mFOLFIRINOX - surgery - 6 cycles of postoperative mFOLFIRINOX improves overall survival by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
Study design: open-label, multicenter, randomized, phase 3 clinical trial Study population: Patients with resectable pancreatic cancer and ECOG performance 0 or 1.
Intervention:
Invervention arm : 6 cycles of neoadjuvant mFOLFIRINOX followed by surgical resection and 6 cycles of adjuvant mFOLFIRINOX Comparator arm : surgical resection followed by 12 cycles of adjuvant mFOLFIRINOX Primary endpoint: 2-year overall survival rate by intention-to-treat
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Jin-Young Jang
- Phone Number: +82-2-2072-2194
- Email: jyjang4@snu.ac.kr
Study Contact Backup
- Name: Myung-Ah Lee
- Email: angelamd@catholic.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Department of Surgery, Seoul National University College of Medicine
-
Seoul, Korea, Republic of, 06591
- Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University College of Medicine
-
Contact:
- Myung-Ah Lee, M.D., Ph.D.
- Phone Number: +82-3210-3125
- Email: angelamd@gatholic.ac.kr
-
Principal Investigator:
- Myung-Ah Lee, M.D., Ph.D.
-
Sub-Investigator:
- Se Jun Park, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A. Age: 19 to 80 years old B. Patients with a score of 0 - 2 (ECOG) when selecting a study subject C. Pancreatic ductal adenocarcinoma diagnosed by histological examination (histologic or cytopathological) D. Patients evaluated as resectable pancreatic cancer in preoperative imaging as follows (NCCN guidelines for pancreatic adenocarcinoma version 2.2021)
- No arterial tumor contact (celiac asix, superior mesenteric artery, or common hepatic artery).
- No tumor contact with the superior mesenteric vein or portal vein or ≤ 180°contact without vein contour irregularity.
E. No distant metastases on preoperative imaging F. Patients with adequate organ function
- Bone marrow function: WBC 3,000/mm3 or more or ANC 1,500/mm3 or more, platelet ≥ 100K/mm3
- Liver function: Bilirubin ≤ 3 x upper normal limit (≤5.0 mg/dL), AST/ALT ≤ 5 x upper normal limit (<200 IU/L)
- Renal function (Cr clearance ≥ 60 mL/min) or (Cr < 1.5 x upper normal limit) G. Persons physically capable of undergoing surgery H. Those who consented to the clinical trial
Exclusion Criteria:
- Patients who met any of the following criteria are not eligible to participate in this study.
A. Those evaluated as borderline resectable or locally advanced pancreatic cancer in preoperative imaging examination B. Patients with a history of previous pancreatic surgery C. Patients with a history of previous chemotherapy or radiation therapy for pancreatic cancer D. Patients with distant metastases or recurrent pancreatic cancer E. Pancreatic body or tail cancer requiring combined resection of adjacent organs (stomach or kidney) (except for the adrenal gland) F. Patients within five years of diagnosis of other organ malignancies (with the exception of adequately treated non-melanoma skin cancer and carcinoma in situ without evidence of disease) G. Pregnant and lactating women H. Serious concomitant systemic disorders that would compromise the safety of the patient or patient's ability to complete the study at the discretion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neoadjuvant FOLFIRINOX
6 cycles of neoadjuvant mFOLFIRINOX followed by surgical resection and 6 cycles of adjuvant mFOLFIRINOX
|
The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
|
Active Comparator: Upfront Surgery
surgical resection followed by 12 cycles of adjuvant mFOLFIRINOX
|
The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-year survival rate
Time Frame: 2 years
|
The primary objective of this trial is to investigate whether 6 cycles of preoperative mFOLFIRINOX - surgery - 6 cycles of postoperative mFOLFIRINOX improves overall survival by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 5 years
|
Defined as the time from the date of randomization to the date of death from any cause.
Patients who were not reported dead at the time of analysis were censored on the last day they were known to be alive.
|
5 years
|
Resection rate
Time Frame: 3 years
|
Referred to the proportion of patients who underwent curative resection
|
3 years
|
R0 resection rate
Time Frame: 3 years
|
Referred to the proportion of patients with microscopically negative resection margins due to the pathological examinations after the surgery.
In this case, R0 indicated that no tumor was observed within 0 mm from the margins of resection.
|
3 years
|
Disease free survival
Time Frame: 3 years
|
Defined as the time between the date of randomization and the occurrence of distant metastases, locoregional progression, or death from any cause.
Patients who were alive and free of these events at the last follow-up would be censored.
|
3 years
|
Recurrence rate
Time Frame: 3 years
|
Local recurrence is defined as recurrence in the pancreatic resection margin, residual pancreas, and regional lymph nodes, and distant metastasis is defined as recurrence in a distant organ.
The local recurrence and distant metastasis rates are defined as the percentage of patients who had recurrence after the surgical resection.
|
3 years
|
Response rate in neoadjuvant setting
Time Frame: 3 years
|
Defined as the percentage of patients who showed complete response, partial response, and stable disease after three or six cycles of scheduled chemotherapy.
The evaluation is based on RECIST v.1.1.
|
3 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Wooil Kwon, Seoul National University Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-2211-115-1380
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Resectable Pancreatic Cancer
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
-
National Cancer Institute (NCI)RecruitingPancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic CarcinomaUnited States
-
Kimberly Perez, MDNovartisTerminatedPancreatic Cancer | Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gangnam Severance HospitalCompletedResectable Pancreatic AdenocarcinomaKorea, Republic of
-
M.D. Anderson Cancer CenterRecruitingBorderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic AdenocarcinomaUnited States
-
Wakayama Medical UniversityRecruitingResectable Pancreatic Body/Tail CarcinomaJapan
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
Clinical Trials on Folfirinox
-
Fox Chase Cancer CenterRecruitingMetastatic Pancreatic CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedCholangiocarcinomaNetherlands
-
Asan Medical CenterGreen Cross Corporation; Boryung Pharmaceutical Co., LtdRecruitingUrachal CancerKorea, Republic of
-
Instituto do Cancer do Estado de São PauloRecruitingGastric CancerBrazil
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruitingMetastatic Colorectal CancerFrance
-
King Faisal Specialist Hospital & Research CenterTerminatedBiliary Tract CancerSaudi Arabia
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingMetastatic Pancreatic CancerFrance
-
Cantargia ABCompletedMetastatic Pancreatic Ductal AdenocarcinomaSpain, France
-
Azienda Ospedaliero, Universitaria PisanaCompletedPancreatic Cancer Non-resectableItaly
-
The University of Texas Health Science Center,...WithdrawnPancreatic Adenocarcinoma